10 June 2021

Jo Huiqing Zhou (Molecular Developmental Biology, Human Genetics, Theme Reconstructive and regenerative medicine) has received two multi-center grants, as the coordinator, for projects aiming at improving patient care and developing regeneration methods for cornea damage patients.

Cornea damage can lead to blindness and severely impair a patients' quality of life. The state-of-the-art treatment is a stem cell-based transplantation therapy that requires cornea stem cells from the patient's uninjured eye to regenerate the transparent cornea. For patients with two injured eyes, this treatment becomes impossible and blindness follows.

The ZonMw Open grant (750K euro), CorneaRegID, is a collaborative project between Maastricht University MERLN Institute, Maastricht UMC+ and Radboud University/Radboudumc. This project uses a data-driven approach to develop a novel transdifferentiation method by converting patient’s cell from other sources, such as skin or oral mucosa, to cornea stem cells for efficient corneal regeneration, thereby restoring vision and preventing blindness. For this, they will apply single-cell multi-omics approaches to identify the precise cell fates of cornea stem cells and cells of the skin and oral mucosa from the same donors. These cell fate maps will guide rational design of genetic modification-free transdifferentiation strategies suitable for transplantation.

Another grant (193K euro) funded by Velux Stiftung that focuses on improving eyesight research in low- and middle income countries is an international endeavor with collaboration of clinicians and scientists in Palestine, Israel and the Netherlands. Part of the project will focus on training of Palestinian ophthalmologists for improving phenotyping and diagnosis, identifying genetic conditions of cornea diseases and preparing for future transplantation. The other part of the project is to characterize and improve existing suboptimal transdifferentiation methods for future transplantation. This project focuses specifically on vision problems in Palestinian territories, but the technology will benefit cornea patients world-wide. 

Related news items


Surprisingly dominant cause underlying type I congenital defect of glycosylation

21 October 2021

Alex Garanto, Melissa Bärenfänger, Mirian Janssen, and Dirk Lefeber published a new study, identifying a surprisingly dominant genetic cause underlying type I congenital defect of glycosylation with neuromusculoskeletal phenotypes.

read more

Sensitive blood-test as a patient-friendly alternative for bone marrow-based cancer monitoring

20 October 2021

Hans Jacobs and Pieter Langerhorst, theme Cancer development and immune defense, and colleagues are one step closer to implementation of personalized diagnostics for bone marrow-based cancer monitoring.

read more

Register for peer coaching for RIMLS PhD candidates

20 October 2021

As a PhD candidate, you are in the lead of your own learning process, but you don’t need to do this alone. Register for the peer-coaching group ‘Stay in the lead – Together’ before 11 November 2021.

read more

Frans Russel appointed member Supervisory Committee of RIVM

20 October 2021

Frans Russel, theme Renal disorders, has been appointed by The Minister of Health, Welfare and Sport (VWS).

read more

Turbo Grants for four medical-technical research projects

19 October 2021

Four TURBO grants were recently awarded to new technical-medical research proposals. The grants are part of the TURBO program, a collaboration between the University of Twente (TechMed Centre) and the Radboudumc.

read more